UK companies want quicker EMA approval for certain drugs
- The European Medicines Association (EMA) has developed a new licensing structure to expedite access to new drugs.
- UK trade associations have responded positively to this new structure--"adaptive licensing."
- The underlying challenge is the need to get novel treatments to market more quickly.
Only certain new drug applications will be accepted for adaptive licensing, which involves early approval of a drug in a restricted patient population, followed by a stepwise process of conducting clinical trials and gathering evidence.
- www.pharmatimes.com UK likes the look of EMA quicker approvals pilot